| Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma M Martello, A Poletti, E Borsi, V Solli, L Dozza, S Barbato, E Zamagni, ... Blood cancer journal 12 (1), 15, 2022 | 18 | 2022 |
| The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases I Vigliotta, S Armuzzi, M Barone, V Solli, I Pistis, E Borsi, B Taurisano, ... Frontiers in Oncology 12, 1001048, 2022 | 3 | 2022 |
| Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma K Mancuso, E Zamagni, V Solli, L Gabrielli, M Leone, L Pantani, S Rocchi, ... Frontiers in Oncology 13, 1208741, 2023 | 2 | 2023 |
| Identification of a maturation plasma cell index through a highly sensitive droplet digital PCR assay gene expression signature validation in newly diagnosed multiple myeloma … M Martello, V Solli, R Termini, A Kanapari, D Remondini, E Borsi, A Poletti, ... International Journal of Molecular Sciences 23 (20), 12450, 2022 | 1 | 2022 |
| BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles G Mazzocchetti, A Poletti, V Solli, E Borsi, M Martello, I Vigliotta, S Armuzzi, ... Computational and Structural Biotechnology Journal 20, 3718-3728, 2022 | 1 | 2022 |
| OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading M Martello, A Poletti, E Borsi, B Taurisano, V Solli, S Armuzzi, ... Clinical Lymphoma Myeloma and Leukemia 21, S37, 2021 | 1 | 2021 |
| Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma C Terragna, A Poletti, V Solli, M Martello, E Borsi, L Pantani, A Lakpo, ... Blood 134, 1778, 2019 | 1 | 2019 |
| Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients E Borsi, I Vigliotta, A Poletti, G Mazzocchetti, V Solli, L Zazzeroni, ... Cells 13 (8), 657, 2024 | | 2024 |
| Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features C Terragna, A Poletti, V Solli, M Martello, E Zamagni, L Pantani, E Borsi, ... Nature Communications 15 (1), 1551, 2024 | | 2024 |
| High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients E Borsi, G Mazzocchetti, AF Dico, I Vigliotta, M Martello, A Poletti, V Solli, ... Clinical and Experimental Medicine 23 (8), 5227-5239, 2023 | | 2023 |
| Genome Sequencing to Discover Drivers of Clonal Expansion in Smoldering Multiple Myeloma JB Alberge, AK Dutta, ED Lightbody, A Poletti, S Wallin, A Dunford, ... Blood 142, 4143, 2023 | | 2023 |
| High Level of Circulating Tumour DNA at Diagnosis Correlates With Disease Spreading and Defines Multiple Myeloma Patients With Poor Prognosis M Martello, B Taurisano, V Solli, G Mazzocchetti, A Poletti, E Borsi, ... The Journal of Liquid Biopsy 1, 2023 | | 2023 |
| P-068 Implementation of next generation sequencing as best tool for routine evaluation of minimal residual disease in the daily practice of multiple myeloma patients S Armuzzi, M Martello, B Taurisano, I Vigliotta, I Pistis, V Solli, E Borsi, ... Clinical Lymphoma Myeloma and Leukemia 23, S72, 2023 | | 2023 |
| P-370 CoMMsol: a machine learning model for outcome-specific copy number alterations' clonality cut-offs definition in multiple myeloma V Solli, A Kanapari, G Mazzocchetti, A Poletti, I Vigliotta, M Martello, ... Clinical Lymphoma Myeloma and Leukemia 23, S243-S244, 2023 | | 2023 |
| OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma A Poletti, JB Alberge, G Mazzocchetti, V Solli, A Kanapari, E Borsi, ... Clinical Lymphoma Myeloma and Leukemia 23, S14, 2023 | | 2023 |
| P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS I Vigliotta, V Solli, S Armuzzi, A Kanapari, A Poletti, B Taurisano, I Pistis, ... HemaSphere 7 (S3), e182325c, 2023 | | 2023 |
| TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutive history of multiple myeloma A Poletti alma, 2023 | | 2023 |
| A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies A Poletti, S Delle Vedove, G Mazzocchetti, V Solli, A Kanapari, E Borsi, ... Blood 140 (Supplement 1), 1559-1560, 2022 | | 2022 |
| Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability JB Alberge, AK Dutta, ED Lightbody, A Poletti, A Dunford, O Priebe, ... Blood 140 (Supplement 1), 4257-4258, 2022 | | 2022 |
| P-077: Multiple myeloma genomic landscape explored by dimensional scaling technique highlights the presence of 1q&13+ patients with specific genomic, transcriptional and … C Terragna, A Poletti, V Solli, M Martello, E Borsi, E Zamagni, L Pantani, ... Clinical Lymphoma Myeloma and Leukemia 22, S77-S78, 2022 | | 2022 |
Michele CavoProfessor of HematologyVerified email at unibo.it
